Essa Pharma Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Essa Pharma Inc's ROI in the third quarter of 2025?
Essa Pharma Inc recorded a cumulative net loss of $-25 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -21.68%.

Within the Healthcare sector 313 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3013 to 3127.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2025) III. Quarter	(Mar 31 2025) II. Quarter	(Dec 31 2024) I. Quarter	(Sep 30 2024) IV. Quarter	(Jun 30 2024) III. Quarter
Y / Y Investment Change TTM	-15.14 %	-14.75 %	-14.6 %	-13.95 %	-13.6 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	109	114	119	125	129
Return On Investment (TTM)	-21.68 %	-23.43 %	-24.57 %	-21.6 %	-20.14 %
EPIX's Overall Ranking	# 3127	# 3013	# 653	# 3147	# 2050
Seq. Investment Change TTM	-4.15 %	-3.98 %	-4.16 %	-3.79 %	-3.71 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-25	-28	-31	-29	-28

EPIX Company Profile >> Back to EPIX Roi Comparisons >> See Annual EPIX Return On Investment

Return On Investment EPIX's Ranking
Within:	No.
Industry	# 110
Sector	# 314
Overall	# 3127

Return On Investment Statistics
High	Average	Low
-17.25 %	-28.55 %	-119.89 %
(Jun 30 2023)		(Sep 30 2018)

Financial Statements
Essa Pharma Inc's III. Quarter Investments	$ 109 Millions	EPIX's Balance sheet
Essa Pharma Inc's III. Quarter Income	$ -4 Millions	Quarterly EPIX's Income Statement
EPIX's Income by Division		See EPIX's Income by Division

EPIX Annual Return On Investment	(Sep 30 2024) 2024	(Sep 30 2023) 2023	(Sep 30 2022) 2022	(Sep 30 2021) 2021	(Sep 30 2020) 2020
Total Investments in Millions	125	146	167	194	79
Y / Y Investment Growth	-14.29 %	-12.9 %	-13.92 %	144.72 %	61.93 %
Net Income in Millions	-29	-27	-35	-37	-23
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-22.87 %	-18.25 %	-21 %	-18.95 %	-29.54 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EPIX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EPIX's Competitors
Subscribers only: Roi for Essa Pharma Inc's Suppliers
Subscribers only: Return On Investment for EPIX's Customers

Other Ratios
EPIX's Roa	EPIX's Inventory Turnover Ratio	EPIX's Growth Rates	EPIX's Dividend Statistics
	EPIX's Profitability Ratios	EPIX's Asset Turnover Ratio	EPIX's Dividend Growth
EPIX's Roe	EPIX's Valuation Ratios	EPIX's Financial Strength Ratios	EPIX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector

ROI

Date modified: 2026-09-08T17:33:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.